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A B S T R A C T
An urgent need exists to develop new antibacterial drugs for children. We conducted research with investigators
of pediatric antibacterial drug trials to identify facilitators and barriers in the conduct of these trials. Seventy-
three investigators completed an online survey assessing the importance of 15 facilitators (grouped in 5 topical
categories) and the severity of 36 barriers (grouped in 6 topical categories) to implementing pediatric anti-
bacterial drug trials. Analysis focused on the identification of key factors that facilitate the successful im-
plementation of pediatric antibacterial drug trials and the key barriers to implementation. Almost all in-
vestigators identified two factors as very important facilitators: having site personnel for enrollment and having
adequate funding. Other top factors were related to staffing. Among the barriers, factors related to parent
concerns and consent were prominent, particularly obtaining parental consent when there was disagreement
between parents, concerns about the number of blood draws, and concerns about the number of invasive pro-
cedures. Having overly narrow eligibility criteria was also identified as a major barrier. The survey findings
suggest three areas in which to focus efforts to help facilitate ongoing drug development: (1) improving en-
gagement with parents of children who may be eligible to enroll in a pediatric antibacterial drug trial, (2)
broadening inclusion criteria to allow more participants to enroll, and (3) ensuring adequate staffing and es-
tablishing sustainable financial strategies, such as funding pediatric trial networks. The pediatric antibacterial
drug trials enterprise is likely to benefit from focused efforts by all stakeholders to remove barriers and enhance
facilitation.
1. Introduction
Before the late 1990s, therapeutic drugs were not regularly eval-
uated for their safety and efficacy in children, leaving pediatricians to
rely largely on data from adult studies, as well as on trial and error, to
inform their treatment decisions [1]. In 1997, the U.S. Congress enacted
the Food and Drug Administration Modernization Act [2], which en-
couraged the voluntary conduct of pediatric drug trials and also man-
dated that pharmaceutical companies conduct pediatric studies in cer-
tain situations. In 2002, an amendment called the Best Pharmaceuticals
for Children Act (BPCA) [3,4] provided companies with a financial
incentive of market and patent exclusivity if they conduct a pediatric
trial at the request of the FDA. In other legislation, the Pediatric Re-
search Equity Act (PREA) of 2003 [3] required that companies devel-
oping drugs for adults conduct pediatric trials unless a waiver is ob-
tained.
Since the initiation of BPCA, PREA, and the regulatory requirement
to register pediatric drug trials, many such trials have been conducted
and drug label updates approved. Between September 27, 2007, and
September 10, 2013, 469 pediatric studies were conducted, including
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studies on efficacy and safety, pharmacokinetics and safety, safety ex-
clusively, and studies of other clinical importance to pediatric popula-
tions [5]. Additionally, 535 pediatric label changes have been approved
as of July 31, 2015 [6]. Yet, an FDA-commissioned review by the Na-
tional Academy of Medicine (formerly the Institute of Medicine) con-
cluded that challenges remain in the conduct of pediatric drug trials,
including the reluctance among parents and physicians to enroll chil-
dren in trials [7,8].
In the field of antibacterial drug development, the number of new
drugs developed has steadily declined over the past several decades [9],
and the current pipeline is “alarmingly thin.” [10] There also remains
an urgent need for the study of new antibacterial drugs for the pediatric
population, especially those that are effective for multidrug-resistant
gram negative infections [11]. Conducting antibacterial drug trials with
children is more challenging than with adults, making it difficult to
comply with PREA, despite considerable efforts [7]. Recent research
has demonstrated that far fewer pediatric antibacterial drug trials are
conducted relative to studies for other pediatric conditions: less than
1% (n=82/12,703) of all interventional and observational pediatric
studies registered in ClinicalTrials.gov between October 2007 and
September 2015 examined antibacterial drugs.[Dr. Joshua Thaden,
personal communication, December 21, 2017] Limited information
exists on the challenges of conducting pediatric clinical trials from the
investigators' perspectives, particularly antibacterial drug trials.
The Clinical Trials Transformation Initiative (CTTI), a pub-
lic–private partnership between the FDA and Duke University, im-
plemented a multifaceted project to address this concern. The project
team—comprised of experts from industry, academia, patient groups,
and the FDA—conducted several studies to identify the scientific and
operational factors involved in conducting pediatric antibacterial drug
trials [12]. In this article, we describe the findings from one of those
studies: a survey of investigator perceptions of the barriers to and the
important facilitators of successful implementation of pediatric anti-
bacterial drug trials.
2. Methods
We conducted an online survey (Qualtrics software, Provo, UT) with
a convenience sample of investigators of pediatric antibacterial drug
trials. Because a record or list of all investigators of pediatric drug trials
did not exist, we recruited investigators through professional net-
working and pediatric member organizations. Members of the CTTI
Steering Committee and the project team identified potential survey
respondents based on their knowledge of U.S.-based investigators of
pediatric antibacterial drug trials. Those investigators, together with
members of six sections of the American Academy of Pediatrics (AAP)
(Clinical Pharmacology & Therapeutics, Infectious Diseases, Critical
Care, Hospital Medicine, Advances in Therapeutics and Technology,
and Neonatal-Perinatal Medicine), were sent an email invitation de-
scribing the purpose of the online survey and requesting their partici-
pation; members of AAP were asked to respond if they had ever con-
ducted a pediatric antibacterial drug trial. Investigators were also asked
to forward the survey invitation to other investigators they knew who
conduct pediatric antibacterial drug trials. The survey was administered
over a 5-week period in August and September 2015.
After asking limited demographic questions, we presented re-
spondents with 15 potential facilitators of successful pediatric anti-
bacterial drug trials, arranged in 5 categories: (1) access to potential
study participants, (2) staff support, (3) clinic space, (4) finance, and
(5) miscellaneous. Respondents were asked to use a four-point Likert
scale to rate the degree of importance of each facilitator: very im-
portant, somewhat important, somewhat unimportant, or unimportant.
Next, we presented respondents with 36 potential barriers to pediatric
antibacterial drug trials, arranged in 6 categories: (1) study protocol,
(2) ethics and regulatory, (3) parental concerns, (4) parent and child
logistics, (5) concerns of colleagues (i.e., fellow physicians), and (6)
miscellaneous. Respondents were again asked to use a four-point Likert
scale to rate the severity of each barrier: major, moderate, somewhat, or
not a barrier. All items were identified by the project team members
based on their experience with pediatric antibacterial drug trials. By
assessing the importance and severity of these potential facilitators and
barriers, we aimed to identify which items were perceived by in-
vestigators to be the key factors in supporting and impeding the suc-
cessful conduct of pediatric antibacterial drug trials. Last, we asked
respondents to describe the three most significant challenges they have
faced in the conduct of pediatric antibacterial drug trials. For all closed-
ended questions, respondents could choose “not applicable” if they had
not encountered the issue or “not sure” if they were uncertain about the
answer. Open-ended questions were also asked throughout, allowing
respondents to list other factors encountered when conducting pediatric
antibacterial drug trials. No distinction was made between inpatient
and outpatient sites for study conduct.
Descriptive statistics were used to summarize the closed-ended
questions. For the open-ended questions, we grouped responses by
overall themes and then documented the frequency of each theme. We
received a determination of exempt status by the Duke University
Health System Institutional Review Board. Respondents agreed to par-
ticipate in the survey by activating the link and initiating the online
survey.
3. Results
3.1. Study population
Of the 101 participants who responded to the survey invitation, 28
were excluded from participating, either because they had not pre-
viously conducted a pediatric antibacterial drug trial (n= 21) or be-
cause they did not answer any question after the demographic section
of the survey (n= 7). The final sample size was 73.
Many respondents were specialists in pediatric infectious diseases
(48%) or neonatologists (23%). The majority had conducted pediatric
antibacterial drug trials for more than 10 years (53%) and at academic
children's hospitals (88%) (Table 1). Almost all associated hospitals had
a neonatal intensive care unit (99%).
Table 1
Respondent characteristics, n (%).
Variable n= 73
Specialtya
Pediatric infectious disease 35 (47.9)
Neonatologist 17 (23.3)
Pediatric intensivist 8 (11.0)
Pediatrician (general) 7 (9.6)
Pharmacologist 7 (9.6)
Pediatric hematologist/oncologist 0 (0)
Otherb 10 (13.7)
Years conducting pediatric antibacterial drug trials
Less than 5 years 20 (27.4)
5–10 years 14 (19.2)
More than 10 years 39 (53.4)
Type of facilitya
Academic children's hospital 64 (87.7)
Large community hospital (e.g. 100 beds) 6 (8.2)
Children's hospital (nonacademic) 4 (5.5)
Private clinic 3 (4.1)
Community clinic 0 (0)
Small community hospital 0 (0)
Otherc 7 (9.6)
a Respondent selected all that applied.
b Pediatric hospital medicine, pediatric nephrologist, pediatric clinical pharmacology,
clinical pharmacologist, pediatric cardiologist, pediatric emergency medicine, pediatric
pulmonologist.
c Pediatric clinical research unit/clinical research unit, academic general hospital/
medical center, integrated health system.
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3.2. Facilitators of the conduct of pediatric antibacterial drug trials
Each factor in all five categories was reported as “very important” or
“somewhat important” for the successful implementation of pediatric
antibacterial drug trials by a high percentage of participants (≥70%)
(Table 2). Two factors especially were recognized as “very important”
facilitators by almost all respondents (96%): having site research per-
sonnel available to assist with enrolling study patients and receiving
adequate funding from sponsors to cover trial implementation costs
other than investigator's salaries. Among the other top “very important”
factors (≥70%), four were related to staffing: having staff with ex-
pertise in regulatory submissions and follow-up (86%); having staff
with expertise in developing and negotiating site budgets (81%); having
staffwith expertise in IRB submissions and follow-up (80%); and having
adequate administrative support for research-related logistical activ-
ities (71%) (Table 3). The remaining top factor was being able to recruit
potential study patients from the investigators' own practice (78%).
When respondents were asked to identify additional facilitators re-
lated to the survey categories, additional factors related to recruitment,
staffing, and funding were common. Eight respondents said that having
established referral systems, such as interdisciplinary collaborations
and access to the hospital inpatient database, were important. Seven
said that staff buy-in, “the willingness of other practitioners to allow
their patients to enroll,” and having good relationships with those who
refer patients were also important factors. Adequate funding, specifi-
cally for study staff, was described by seven respondents. A pediatric
infectious disease specialist stressed the benefit of having dedicated
staff with the “flexibility to enroll the patient with little advance time
warning.” Similarly, having staff available 24 h a day, 7 days a week,
was also described. A neonatologist said, “For inpatient studies, an in-
novative way of managing recruitment 24/7 is important. This has been
the most challenging.” A pharmacologist said, “Having provision for
long-term support of staff so that you are not constantly training new
staff for each new study.” Six respondents focused on the importance of
adequate study coordinator payment. A pediatric infectious disease
specialist said: “Investigators are doing these trials for free. Studies DO
NOT have a budget big enough to even offset the cost of the co-
ordinator. The investigator almost always relinquishes investigator
earmarked dollars toward coordinators, in order not to lose them.”
3.3. Barriers to the conduct of pediatric antibacterial drug trials
Each factor in all six categories was rated as a barrier (“somewhat,”
“moderate,” or “major”) by a considerable percentage of participants
(range: 48.5%–98.6%) (Figs. 1 and 2). In comparison with the other
categories, almost all of the factors in the parental concern category
were identified as a barrier by a high percentage of respondents
(≥80%); factors in the concerns of colleagues category were identified
as barriers by a lower percentage of respondents compared to the other
categories.
Focusing on the “major” barriers, four factors were identified by a
higher percentage of participants compared with other factors. Three of
Table 2
Perceptions of factors important to the successful implementation of pediatric antibacterial drug trials, n (%).
Category Very important Somewhat important Somewhat unimportant Unimportant Not sure NA
Access to potential study participants, n= 73
Being able to recruit potential study patients from my practice 57 (78.1) 11 (15.1) 2 (2.7) 2 (2.7) 0 (0) 1 (1.4)
Having others refer potential patients to your study 38 (52.1) 16 (21.9) 8 (11.0) 7 (9.6) 0 (0) 4 (5.5)
Staff support, n= 73
Having site research personnel assist with enrolling study patients 70 (95.9) 3 (4.1) 0 (0) 0 (0) 0 (0) 0 (0)
Having staff with expertise in regulatory submissions and follow-up 63 (86.3) 10 (13.7) 0 (0) 0 (0) 0 (0) 0 (0)
Having staff with expertise in developing and negotiating budgets 59 (80.8) 13 (17.8) 1 (1.4) 0 (0) 0 (0) 0 (0)
Having staff with expertise in IRB submission and follow-up 58 (79.5) 14 (19.2) 1 (1.4) 0 (0) 0 (0) 0 (0)
Having adequate administrative support for research-related logistical
activities
52 (71.2) 19 (26.0) 1 (1.4) 1 (1.4) 0 (0) 0 (0)
Getting adequate support from clinic or hospital nursing personnel 43 (58.9) 26 (35.6) 3 (4.1) 1 (1.4) 0 (0) 0 (0)
Getting adequate support from clinic or hospital laboratory personnel 33 (45.2) 32 (43.8) 6 (8.2) 2 (2.7) 0 (0) 0 (0)
Partnering with a CRO to facilitate research 21 (28.8) 31 (42.5) 12 (16.4) 6 (8.2) 2 (2.7) 1 (1.4)
Clinic spacea, n= 72
Having adequate clinic space for patient study visits 43 (59.7) 21 (29.2) 2 (2.8) 1 (1.4) 0 (0) 5 (6.9)
Having adequate office space for research administration 29 (40.3) 35 (48.6) 8 (11.1) 0 (0) 0 (0) 0 (0)
Finance, n= 73
Receiving adequate funding from sponsor to cover trial implementation
costs other than investigator salaries a
69 (95.8) 3 (4.2) 0 (0) 0 (0) 0 (0) 0 (0)
Receiving adequate funding from sponsor for the investigators' salary b 45 (63.4) 18 (25.4) 5 (7.0) 3 (4.2) 0 (0) 0 (0)
Miscellaneous a, n= 72
Using electronic data collection and medical record management 35 (48.6) 34 (47.2) 1 (1.4) 2 (2.8) 0 (0) 0 (0)
CRO= contract research organization; NA=not applicable.
a Data missing from one respondent.
b Data missing from two respondents.
Table 3
Perceptions of factors that are very important to the successful implementation of pediatric
antibacterial drug trials, n (%).
Factor n= 73
Having site research personnel assist with enrolling study patients 70 (95.9)
Receiving adequate funding from sponsor to cover trial
implementation costs other than investigator salaries a
69 (95.8)
Having staff with expertise in regulatory submissions and follow-up 63 (86.3)
Having staff with expertise in developing and negotiating site
budgets
59 (80.8)
Having staff with expertise in IRB submissions and follow-up 58 (79.5)
Being able to recruit potential study patients from my practice 57 (78.1)
Having adequate administrative support for research-related
logistical activities
52 (71.2)
Receiving adequate funding from sponsor for the investigator salary b 45 (63.4)
Having adequate clinic space for patient study visits a 43 (59.7)
Getting adequate support from clinic or hospital nursing personnel 43 (58.9)
Having others refer potential patients to your study 38 (52.1)
Using electronic data collection and medical record management a 35 (48.6)
Getting adequate support from clinic or hospital laboratory personnel 33 (45.2)
Having adequate office space for research administration a 29 (40.3)
Partnering with a clinical research organization to facilitate the
research
21 (28.8)
IRB= institutional review board.
a Data missing from one respondent.
b Data missing from two respondents.
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these were related to parental involvement and consent: obtaining
parental consent when disagreement between parents is evident (51%),
concerns about the number of blood draws (47%), and concerns about
the number of invasive procedures (44%). The remaining major barrier
was having overly narrow inclusion/exclusion criteria (43%) (Figs. 1
and 2).
3.4. Top challenges highlighted by respondents
From the open-ended responses, we identified three main themes on
the most significant challenges respondents (n= 59) experienced in
conducting pediatric antibacterial drug trials.
Trial finances were mentioned most often (n=27). Respondents
stressed that budgets were insufficient to cover trial costs. A few de-
scribed the difficulties caused by inadequate funding, such as a pedia-
tric pharmacologist who said “finding study coordinators with suffi-
cient experience given the meager remuneration afforded from the low-
cost studies” was a significant challenge. A pediatrician explained that
inadequate funding has led to the “inability to compensate study staff
adequately for their time and expertise.”
The difficulties investigators faced in identifying, recruiting, and
efficiently enrolling the necessary number of eligible patients were also
frequently described (n= 23). Many focused their responses on their
inability to enroll sufficient numbers of patients because of overly
narrow inclusion and exclusion criteria. For example, a pediatric
infectious disease specialist said, “very narrow inclusion/exclusion
criteria make it inefficient to screen patients unless financial support is
sufficient.”
Last, parental consent was identified by many respondents (n=20).
A few explained that the requirement for documenting informed con-
sent from two parents and the lack of direct benefit to the child from
study participation made obtaining parental consent difficult. A neo-
natologist described this challenge as “obtaining consent when the
parents see no direct benefit for their child and are happy with current
care.”
4. Discussion
Our purpose in conducting this survey was to identify—from the
perspective of pediatric investigators who conduct antibacterial drug
trials—the key factors that contribute to the successful implementation
of such trials and the key barriers that make implementation difficult.
Our findings demonstrate that a high percentage (≥70%) of re-
spondents agreed that the 15 potential facilitators presented were im-
portant (“very” or “somewhat”) to success. Further, several barriers
highlighted by respondents provided critical insights into their current
challenges, demonstrating the complex nature of conducting such trials.
To begin to address these challenges, it is important to both enable
the most significant facilitators and remove the major barriers. Several
areas provide opportunities to focus effort. The first area is improved
Fig. 1. Perceptions of potential barriers related to pediatric antibacterial study protocols, ethics and regulatory processes, and colleagues' concerns about pediatric antibacterial trials, %.
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engagement with parents of children who may be eligible to enroll in a
pediatric antibacterial drug trial. Investigators should consider how to
address the parental concerns identified in this survey when designing
their trials, such as reducing the number of blood draws where possible.
It is also the investigator's responsibility to communicate information
about a trial and its implications in the most effective and under-
standable way so that parents can make an informed decision about
their child's participation. Parents need to understand clearly the po-
tential benefits and risks so they can make the best decision for their
child. However, even with effective communication, parents still may
be only willing to accept a minimal level of risk to their child's health,
making the implementation of some trials challenging.
A second area of effort involves the recognition that strict eligibility
criteria have a negative impact on trial enrollment. Sponsors and in-
vestigators should consider situations where broader inclusion criteria
could apply, including allowing for some effective antibacterial drugs
prior to enrollment, and where trials can be streamlined. However, the
safety of antibacterial drugs for all pediatric age groups is important to
evaluate, mandating that reasonable data be collected on clinical and
laboratory adverse events, in addition to clinical and microbiologic
outcomes. Even with attempts to streamline trials, some studies may
simply take longer to enroll, particularly for the youngest age groups.
The third area of effort involves staffing and financial strategies.
There is value in setting up and funding pediatric trial networks that
can help facilitate ongoing drug development and also eliminate the
need for startup with each new trial. Trial networks can help to stan-
dardize the requirements for site resources and funding. A last funding
consideration is that sites must submit realistic budgets that will fully
support the staffing necessary for success—and sponsors likewise
should be prepared to fund these trials with realistic costs.
We acknowledge that our findings are preliminary given our sam-
pling strategy. We would have preferred to sample a definitive group of
investigators of pediatric antibacterial drug trials, but such a group does
not exist to our knowledge. We therefore attempted to reach as many
investigators as possible. Nevertheless, our findings provide insight into
the facilitators and challenges experienced by investigators of pediatric
antibacterial drug trials and can help to focus efforts to encourage the
conduct of such trials.
While investigators of pediatric antibacterial drug trials face many
challenges, they are keenly aware of the factors that can lead to suc-
cessful implementation. The pediatric antibacterial drug trials en-
terprise can likely benefit from focused efforts by all stakeholders in
drug development and approval that will remove barriers, expand and
enable facilitators, and engender the crucial support of trial sponsors.
Fig. 2. Perceptions of potential barriers related to parental concerns and parent or child logistics.
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